Biogen Senses 'Interesting Opportunities' If Financial Markets Remain Challenging
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm earmarks $100m for business development in 2016, and says the market appears to be turning in favor of buyers.
You may also be interested in...
Spotlight Returns To Biogen R&D To Sustain Success
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.
Merck & Co. Pauses Enrollment Of Oral Islatravir In PrEP Studies As Bad News Mounts
Merck has already paused other studies testing the potential first-in-class NRTTI and is adding additional monitoring of lymphocyte and CD4+ T-cell assessments.
Novartis Slips Into Pfizer's Number One Pharma Slot Amid Leaderboard Shakeup
Pfizer has dropped to number seven in our top pharma rankings after a long reign. AbbVie has risen to number three, growing through merger expansion.